Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

Clinical Q&A

Barbara Holmes Gobel
CJON 2002, 6(3), 177-180 DOI: 10.1188/02.CJON.177-180

We have observed an increase in the incidence of paclitaxel-related hypersensitivity reactions at our institution. Does any new information explain the etiology of these reactions? Should we change our standards for monitoring patients receiving paclitaxel infusions (e.g., begin placing patients on cardiac monitors)?

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or